Efficacy of levosimendan infusion in patients undergoing a left ventricular assist device implant in a propensity score matched analysis of the EUROMACS registry—the Euro LEVO-LVAD study

Autor: Mahmoud Abdelshafy, Kadir Caliskan, Andrew J Simpkin, Ahmed Elkoumy, Jesse R Kimman, Hagar Elsherbini, Hesham Elzomor, Theo M M H de By, Can Gollmann-Tepeköylü, Michael Berchtold-Herz, Antonio Loforte, David Reineke, Felix Schoenrath, Lech Paluszkiewicz, Jan Gummert, Paul Mohacsi, Bart Meyns, Osama Soliman
Přispěvatelé: Cardiology, Intensive Care, Cardiothoracic Surgery
Rok vydání: 2023
Předmět:
Zdroj: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 63(5). Elsevier
ISSN: 1873-734X
1010-7940
Popis: OBJECTIVES Early right-sided heart failure (RHF) was seen in 22% of recipients of a left ventricular assist device (LVAD) in the European Registry for Patients with Mechanical Circulatory Support (EUROMACS). However, the optimal treatment of post-LVAD RHF is not well known. Levosimendan has proven to be effective in patients with cardiogenic shock and in those with end-stage heart failure. We sought to evaluate the efficacy of levosimendan on post-LVAD RHF and 30-day and 1-year mortality. METHODS The EUROMACS Registry was used to identify adults with mainstream continuous-flow LVAD implants who were treated with preoperative levosimendan compared to a propensity matched control cohort. RESULTS In total, 3661 patients received mainstream LVAD, of which 399 (11%) were treated with levosimendan pre-LVAD. Patients given levosimendan had a higher EUROMACS RHF score [4 (2– 5.5) vs 2 (2– 4); P CONCLUSIONS In this analysis of the EUROMACS registry, we found no evidence for an association between levosimendan and early RHF or death, albeit patients taking levosimendan had much higher risk profiles. For a definitive conclusion, a multicentre, randomized study is warranted.
Databáze: OpenAIRE
Externí odkaz: